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In this study we compared the performance of the Chagas Stat-Pak rapid immunochromatographic test with
a standard enzyme-linked immunosorbent assay (ELISA) in the serodiagnosis of Chagas’ disease in Central
America. Out of 3,400 blood donor samples, 156 (4.6%) were positive in both assays. Three sera out of 2,084
samples from reference laboratories were negative with the rapid test but positive with the ELISA (99.8%
agreement). Agreement of 100% between the two tests was observed with 339 additional sera from patients with
cardiopathies and 175 sera from potential blood donors in emergency surgical cases occurring on weekends or
at night. In conclusion, Chagas Stat-Pak showed 99.6% and 99.9% sensitivity and specificity, respectively, when
assayed with 5,998 serum samples. It is a sensitive and specific alternative to the ELISA, as required in medical
emergencies and blood screenings in Central America.
Chagas’ disease, or American trypanosomiasis, is caused by
the hemoflagellate protozoan Trypanosoma cruzi and is a ma-
jor public health problem in Central America, where the esti-
mated seroprevalence of infection is 7% (10, 13). T. cruzi is
naturally transmitted to mammalian hosts through the urine
and feces of infected hematophagous bugs or by blood trans-
fusion or the ingestion of contaminated food; it may also be
transmitted congenitally or through organ transplantation (10,
13). In Honduras, 20% of chronic cardiopathies are from cha-
gasic patients, and 36% of pacemakers implanted in Guate-
mala and Honduras are for arrhythmias due to chagasic car-
diopathy (7).
Chagas’ disease is routinely diagnosed by commercial sero-
logical methods, such as enzyme-linked immunoassays
(ELISAs), indirect immunofluorescence (IIF), and indirect
hemagglutination, which use whole or semipurified extracts of
the epimastigotes of T. cruzi. A considerable variation in the
reproducibility and reliability of the results is observed with the
three methods (1). The conventional serological tests (ELISA
and IIF) are time-consuming (3 to 4 h) and consist of several
steps, thus increasing the possibility of operational error (1, 4).
An ELISA can be automated but at an increased cost that is
beyond the reach of most laboratories in Central America.
Therefore, many blood banks, routine diagnostics laboratories,
and peripheral hospitals test a small number of samples per
day, and, in general, these centers cannot afford the equipment
and technicians needed to carry out the above-mentioned tests.
Nonconventional serological tests based on recombinant
proteins or synthetic peptides have shown promising results for
the diagnosis of T. cruzi infection (2, 3). These tests may,
however, need to be adapted to local conditions. Umezawa et
al. 2003 (11) have recently reported the combination of three
T. cruzi recombinant antigens in a single ELISA, resulting in a
multiantigen test that is very sensitive and specific for the
diagnosis of Chagas’ disease. On the basis of these results, a
novel rapid immunochromatographic assay (Chagas Stat-Pak)
was developed employing a defined mixture of these recombi-
nant antigens (5). This test presents several advantages such as
simplicity (one step), short execution time, absence of a need
for special equipment or expertise, and, consequently, the pos-
sibility of use in the field at reduced cost. In addition, the
option of storing the results indefinitely allows for subsequent
confirmation by specialized staff.
With increasing interest in rapid diagnostic testing, labora-
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tories are reviewing their ordering options for immunoassay
kits to include in their routine protocols. Here we present the
evaluation of Chagas Stat-Pak performance in a large field
study in Central America. The test was used in the following
situations: prescreening of random blood donors, selection of
blood bags for transfusion in emergency surgical cases, and
confirmation of diagnosis in cases of cardiopathy and other
conditions. This study shows the advantages of employing this
diagnostic tool in regions where Chagas’ disease is endemic.
MATERIALS AND METHODS
Immunochromatographic assay. Chagas Stat-Pak (Chembio Diagnostic Sys-
tems, Medford, NY) is a rapid immunochromatographic screening test for de-
tection of anti-T. cruzi antibodies in whole blood, serum, or plasma (5). It
employs a unique combination of T. cruzi recombinant antigens (B13, 1F8, and
H49/JL7) (described in reference 11), which are bound to the membrane, and a
specific antibody-binding protein, which is conjugated on dye particles. As the
test sample flows laterally through the membrane, the antibody-binding protein-
dye conjugate binds to human immunoglobulins in the sample. A drop of serum
(5 l) is placed in the sample well at the holder, and buffer provided with the kit
is added. After 5 to 15 min, the mixture of serum plus buffer migrates to the top
of the device. The end of the reaction is indicated by a colored line on the top
(positive control). The presence of anti-T. cruzi antibodies in the sample pro-
duces a pink/purple line (positive), whereas in its absence no line appears in the
reaction zone (negative). A second pink/purple line in the control zone confirms
that the reaction was completed and that the test is, hence, validated. Reading of
the results on the appropriate region of the device is performed by recording the
absence of any line as negative and a strong or weak line as positive.
ELISA. All serum samples were also analyzed with a commercial ELISA kit
(Chagatest recombinante; Wiener, Argentina) used routinely in Honduras and
El Salvador. In Nicaragua, the National Center for Diagnostic and Reference
employed an in-house ELISA, prepared with antigens from a local T. cruzi strain
following the technique described by Voller et al. (12).
Study populations. Human sera were obtained from random blood donors and
patients with clinical symptoms consistent with Chagas’ disease. The study was
approved by the institutional review boards of the Secretary of Health, Hondu-
ras, and the human experimentation guidelines of this institution were followed.
The 5,998 serum samples used in this study consisted of the following: (i) samples
collected from candidates for blood donation (n  3,400) at seven blood banks
in Honduras from January to December 2000 (Tables 1 and 2); (ii) samples from
blood donors (n  175) tested only by Chagas Stat-Pak before transfusion, in
emergencies occurring on weekends or at night at the Red Cross Laboratory in
the National Blood Center of Honduras, Tegucigalpa (Table 1); (iii) samples
from patients (n  339) who consulted at the National Thorax Institute of
Honduras and were diagnosed with cardiopathy (Table 1); and (iv) samples
received by reference diagnostic laboratories in Honduras (n  1,684), El Sal-
vador (n  200), and Nicaragua (n  200) for exclusion or confirmation of
Chagas’ disease (Table 1).
Each sample was first tested by the staff of each laboratory with the Chagas
Stat-Pak kit and afterwards by ELISA. Readings were recorded by each observer,
and in the case of doubtful results, a second observer was consulted. In this study,
the ELISA was selected as the gold-standard test. The values for sensitivity and
specificity and for agreement between Chagas Stat-Pak and ELISA were calcu-
lated as described previously (3).
RESULTS
In a previous study, the Chagas Stat-Pak test showed 100%
sensitivity when assayed with sera collected in Honduras (5).
To confirm and extend these results, a larger number of serum
samples (n  2,084) was analyzed with Chagas Stat-Pak and
ELISA in three reference laboratories in Honduras (n 
1,684), Nicaragua (n  200), and El Salvador (n  200) (Table
1). From this total, 1,077 and 1,007 serum samples, respec-
tively, were positive and negative by ELISA, while 1,074 and
1,010 samples, respectively, were positive and negative by Cha-
gas Stat-Pak. This means that three sera with anti-T. cruzi
antibodies were recognized by ELISA but were not detected by
the Chagas Stat-Pak. These three sera with discrepant results
were tested also by IIF and by indirect hemagglutination, with
positive results that were in accord with the ones obtained by
the Wiener ELISA. The agreement between the two tests was
100% with sera from Nicaragua and 99.9% and 97.1% with
sera from Honduras and El Salvador, respectively.
The rapid and accurate diagnosis of Chagas’ disease is im-
perative in order to provide patients at the National Thorax
Institute of Honduras with appropriate treatment and support-
ive therapy. Sera from 339 patients who consulted for the first
time at the National Thorax Institute and were diagnosed as
having cardiopathy were assayed using Chagas Stat-Pak (Table
1). Ninety-seven patients were positive. The same result was
confirmed for all samples with ELISA, with 100% agreement.
Chagas Stat-Pak was tested as a possible tool for use in
emergencies in regions where Chagas’ disease is endemic,
where a donor should be evaluated quickly before his/her
blood is delivered into a severely disabled patient. This situa-
tion is common in remote cities, where few facilities are avail-
TABLE 1. Evaluation of Chagas Stat-Pak in different medical situations in Central Americaa
Country Purpose of test
Total
no. of
samples
Chagas Stat-Pak
(no. of samples)
ELISA
(no. of samples) Agreementb (%)
Pos Neg Pos Neg
Hondurasc Confirmation 1,684 995 689 996 688 99.9
El Salvadord Confirmation 200 67 133 69 131 97.1
Nicara´guae Confirmation 200 12 188 12 188 100
Hondurasf Confirmation 339 97 242 97 242 100
Hondurasg Emergency 175 1 174 1 174 100
Hondurash Exclusion 3,400 156 3,244 156 3,244 100
Total 5,998 1,328 4,670 1,331 4,667 99.8
a Abbreviations: Pos, positive; Neg, negative.
b Agreement between the results obtained with Chagas Stat-Pak and ELISA. In the present study the ELISA was taken as the gold-standard technique.
c Central Reference Laboratory for Chagas’ disease and Leishmaniasis, Secretary of Health, Tegucigalpa, Honduras.
d Central Laboratory, Ministry of Public Health and Social Assistance, San Salvador, El Salvador.
e National Center for Diagnostic and Reference, Ministry of Health, Managua, Nicaragua.
f INS: National Thorax Institute, Tegucigalpa, Honduras.
g CRH-CENASA: Red Cross Laboratory-National Blood Center, Tegucigalpa, Honduras.
h Blood banks. See Table 2 for detailed descriptions of blood banks in Honduras.
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able and where there are limited blood reserves. In such situ-
ations, fast methods should be used, or the patient may die.
Using only Chagas Stat-Pak, the Red Cross Laboratory in
Tegucigalpa (Honduras) tested 175 blood bags in emergencies
that required surgical procedures during weekends or at night.
Results were negative in 99.4% of the sera (n  174); hence,
blood was immediately transfused to the recipients. When
Chagas Stat-Pak showed a positive result, the blood was re-
fused, and blood from another negative donor was used in-
stead. After recipients were transfused in emergencies with
blood tested with Chagas Stat-Pak, the sera were tested with
routine ELISA, which yielded the same results as the rapid
test; i.e., 174 sera tested negative, and the single positive case
detected by Chagas Stat-Pak was confirmed positive by ELISA
(Table 1).
The specificity of Chagas Stat-Pak was estimated in blood
donor populations with both a high and low prevalence of
Chagas’ disease and compared with that of an ELISA using the
same specimens (Table 2). A total of 3,400 candidates for
blood donation were screened by both tests in seven Honduran
blood banks, with 156 positive (4.6%) by Chagas Stat-Pak. All
of them were confirmed by ELISA, which is used routinely,
with 100% agreement. There were no differences in the results
among the seven blood banks that took part in this study for
either test.
DISCUSSION
Most countries in Central America have relatively small
territorial extensions and a high prevalence of T. cruzi-infected
individuals (7, 10, 13). In general, laboratories for the diagnosis
of infectious diseases are small, have few resources, and per-
form a limited number of tests per day. These laboratories,
however, are obliged to include diagnosis of anti-T. cruzi anti-
bodies in candidates for blood donation because of specific
legislation. In addition, in 1997 “The Central American Initia-
tive for the Control of Vectorial and Transfusional Transmis-
sion of T. cruzi” was launched, aiming at the elimination of
insect vectors and the screening of all blood donors (13). There
is, therefore, a need for a rapid and reliable test for Chagas’
disease to be used in these circumstances, and such a test
should be commercially available for immediate use. In addi-
tion, the test should have high specificity and sensitivity and be
validated with sera from Central America in order to be able to
diagnose individuals infected with T. cruzi strains circulating in
these regions (6, 13, 14). Finally, such a test should be suitable
for use with a small number of samples per day. Studies per-
formed with Chagas Stat-Pak and published recently (5) sug-
gest that this test fulfills all these requirements.
The present study was designed to test this hypothesis.
For this purpose, almost 6,000 serum samples, covering
three Central American countries, were tested. The samples
were obtained from reference laboratories, blood banks,
and hospitals. Results showed that the Chagas Stat-Pak per-
formed well with the 5,998 serum samples, of which only 3
tested negative compared with the ELISA (0.05% disagree-
ment). There was perfect agreement with all the samples
from the seven blood banks included in the study. These
findings allow us to recommend Chagas Stat-Pak as a second
test in blood banks and as a single test in emergencies. The
performance of the test in patients presenting cardiopathies
also correlated closely with the results obtained by ELISA.
Other commercial tests are available, such as PaGia (8) and
Innolia (9), but they need to be performed in laboratories,
demand more skill, and involve more steps and, hence,
would not fulfill the requirement of a quick and easy test, as
the Chagas Stat-Pak tested in this study does.
We conclude that Chagas Stat-Pak meets all the require-
ments for use in Central American blood banks and laborato-
ries for confirmation of the infection, as well as in seroepide-
miological studies. In addition, the test can be performed
without the need for special skills and can be used for a small
number of samples. Although the cost of the Chagas Stat-Pak
rapid cartridges is higher than that of a single ELISA, Chagas
Stat-Pak is more economical if the costs associated with labo-
ratory personnel, quality control, and reagent storage are
taken into account.
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